Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

ABSTRACT:

Background

Clinically evident portal hypertension (CEPH) was previously identified as a prognostic factor for patients with hepatocellular carcinoma (HCC). However, little is known about the prognostic influence of CEPH on the long-term outcome of patients with HCC undergoing transarterial chemoembolization (TACE), particularly in Western populations.

Objectives

This study investigated the prevalence and prognostic influence of CEPH in a Western population of patients with HCC undergoing TACE.

Methods

This retrospective study included 349 treatment-naïve patients that received initial TACE treatment at our tertiary care center between January 2010 and November 2020. CEPH was defined as a combination of ascites, esophageal/gastric varices, splenomegaly and a low platel

SUBMITTER: Muller L 

PROVIDER: S-EPMC8830270 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature